Top Integrated Utility Stocks To Buy For 2015

Top Integrated Utility Stocks To Buy For 2015: VIVUS Inc (VVUS)

VIVUS, Inc., incorporated on May 16, 1996, is a biopharmaceutical company. It commercializes and develops therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health. The Company's drug, Qsymia (phentermine and topiramate extended-release) was approved by the the United States Food and Drug Administration (FDA) for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 or greater (obese), or 27 or greater (overweight) in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol (dyslipidemia). Qsymia incorporates low doses of active ingredients from two previously approved drugs, phentermine and topiramate. It has completed Phase 2 clinical studies for Qsymia for the treatment of sleeps apnea and Qsymia for the treatment of type 2 diabetes. Its drug al so includes STENDRA, or avanafil.

Qsymia for the treatment of obesity was approved as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial BMI of 30 or greater (obese), or 27 or greater (overweight) in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol (dyslipidemia). Qsymia incorporates low doses of active ingredients from two previously approved drugs, phentermine and topiramate.

The Company initially launched Qsymia for distribution to eligible patients through the home delivery networks of two certified pharmacies, CVS Pharmacy and Walgreens. Since then, it has expanded the distribution of Qsymia to include the home delivery networks of Express Scripts, Wal-Mart Pharmacy and, for its members only, Kaiser Permanente. Clinical studies of topiramate, a component of Qsymia, in type 2! diabetics resul ted in a clinically reduction of hemoglobin A1c (HbA1c). The! Company's drug, STENDRA (avanafil), is an oral PDE5 inhibitor the Company has licensed from Mitsubishi Tanabe Pharma Corporation (MTPC).

Advisors' Opinion:

• [By Sean Williams]

  The battle over obesity
  Two names in this space that made big waves last year are anti-obesity-drug makers Arena Pharmaceuticals (NASDAQ: ARNA  ) and VIVUS (NASDAQ: VVUS  ) . Arena's Belviq was approved in June -- just weeks before VIVUS' Qsymia -- but its debut has been on hold because of drug labeling by the Drug Enforcement Agency. The good news for shareholders here is that the DEA found the potential for abuse to be relatively low for Belviq, and it's expected to be on pharmacy shelves in as early as two weeks.

• [By Brian Orelli]

  Obesity catfight
  VIVUS (NASDAQ: VVUS  ) will launch fights on two fronts this summer.

  The biotech company's obesity drug Qsymia now has direct competition from Arena Pharmaceuticals (NASDAQ: ARNA  ) and Eisai's recently launched Belviq. I continue to think there's plenty of room for both drugs on the market; obesity is an epidemic after all. But in the short term, it's going to be interesting to see if the launch of Belviq cuts into Qsymia sales.

source from Top Penny Stocks For 2015:http://www.seekpennystocks.com/top-integrated-utility-stocks-to-buy-for-2015.html